ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Seattle, WA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Seattle, WA, USA:

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)

and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...

Enrolling
Multiple Myeloma
Biological: bb2121
Drug: Talquetamab

Phase 2

Celgene
Celgene

Seattle, Washington, United States and 25 other locations

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who c...

Enrolling
Multiple Myeloma
Drug: Ruxolitinib Oral Tablet [Jakafi]
Drug: Methylprednisolone

Phase 1

Oncotherapeutics

Tacoma, Washington, United States and 12 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Active, not recruiting
Multiple Myeloma
Drug: Isatuximab
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Seattle, Washington, United States and 48 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Bendamustine
Drug: CC-95266

Phase 1

Juno Therapeutics

Seattle, Washington, United States and 9 other locations

CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: PHE885

Phase 2

Novartis
Novartis

Seattle, Washington, United States and 35 other locations

of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Bortezomib

Phase 2

AbbVie
AbbVie

Seattle, Washington, United States and 40 other locations

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...

Active, not recruiting
Multiple Myeloma
Drug: Venetoclax
Drug: Carfilzomib

Phase 2

AbbVie
AbbVie

Seattle, Washington, United States and 31 other locations

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Biological: bb2121
Drug: Dexamethasone

Phase 3

Celgene
Celgene

Seattle, Washington, United States and 59 other locations

phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma...

Enrolling
Multiple Myeloma
Drug: Selinexor
Drug: Mezigdomide

Phase 1, Phase 2

Karyopharm Therapeutics
Karyopharm Therapeutics

Seattle, Washington, United States and 24 other locations

Recently updated

progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab SC
Drug: Daratumumab IV

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Seattle, Washington, United States and 211 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems